http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-103356516-A
Outgoing Links
Predicate | Object |
---|---|
assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_49d82b44ab1f5dd60b490f50b9d47231 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_43a38ca973eeaef4061f918b4919b04d |
classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C259-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-166 |
filingDate | 2013-03-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6ca0f98336ef93ba65b5e3b63af3f380 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_803f0eb5e29287623aa8c26b67adf83e |
publicationDate | 2013-10-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber | CN-103356516-A |
titleOfInvention | Small molecule anti-cancer drug based on mitogen-activated protein kinase kinase (MEK) and histone deacetylase (HDAC) double targets and preparation method of small molecule anti-cancer drug |
abstract | The invention discloses a small molecule anti-cancer drug based on mitogen-activated protein kinase kinase (MEK) and histone deacetylase (HDAC) double targets and a preparation method of the small molecule anti-cancer drug and belongs to the technical field of small molecule anti-cancer drugs. The drug has the following chemical structure. The drug is a small molecule anti-cancer drug based on MEK and HDAC double targets, so that the curative effect of the current MEK and HDAC single-target small molecule anti-cancer drug is improved, and the toxic and side effects are reduced. |
isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-110938055-A |
priorityDate | 2013-03-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 222.